| Literature DB >> 34305942 |
Robin Smyth1, Jim Sun1,2.
Abstract
The global antimicrobial resistance crisis poses a significant threat to humankind in the coming decades. Challenges associated with the development of novel antibiotics underscore the urgent need to develop alternative treatment strategies to combat bacterial infections. Host-directed therapy is a promising new therapeutic strategy that aims to boost the host immune response to bacteria rather than target the pathogen itself, thereby circumventing the development of antibiotic resistance. However, host-directed therapy depends on the identification of druggable host targets or proteins with key functions in antibacterial defense. Protein Kinase R (PKR) is a well-characterized human kinase with established roles in cancer, metabolic disorders, neurodegeneration, and antiviral defense. However, its role in antibacterial defense has been surprisingly underappreciated. Although the canonical role of PKR is to inhibit protein translation during viral infection, this kinase senses and responds to multiple types of cellular stress by regulating cell-signaling pathways involved in inflammation, cell death, and autophagy - mechanisms that are all critical for a protective host response against bacterial pathogens. Indeed, there is accumulating evidence to demonstrate that PKR contributes significantly to the immune response to a variety of bacterial pathogens. Importantly, there are existing pharmacological modulators of PKR that are well-tolerated in animals, indicating that PKR is a feasible target for host-directed therapy. In this review, we provide an overview of immune cell functions regulated by PKR and summarize the current knowledge on the role and functions of PKR in bacterial infections. We also review the non-canonical activators of PKR and speculate on the potential mechanisms that trigger activation of PKR during bacterial infection. Finally, we provide an overview of existing pharmacological modulators of PKR that could be explored as novel treatment strategies for bacterial infections.Entities:
Keywords: EIF2AK2; Protein Kinase R; antibacterial defense; autophagy; bacterial infection; cell death; inflammation; macrophage signaling
Mesh:
Substances:
Year: 2021 PMID: 34305942 PMCID: PMC8297547 DOI: 10.3389/fimmu.2021.702142
Source DB: PubMed Journal: Front Immunol ISSN: 1664-3224 Impact factor: 7.561
Figure 1Signaling pathways regulated by PKR to control immune cell functions. PKR regulates downstream effectors such as IPS-1, IKK, and MKK to activate IRF3, NF-κB, and the MAP kinases JNK and p38, respectively. IRF3 induces transcription of IFNβ, whereas NF-κB induces transcription of pro-inflammatory cytokines such as TNFα, IL-1β, and IL-6. Active JNK and p38 trigger c-Jun and ATF2 activation, respectively, which also induce transcription of pro-inflammatory cytokines. PKR also plays a role in induction of pyroptosis via activation of the NLRP1, AIM2, NLRP3, and NLRC4 inflammasomes. Phosphorylation of EIF2α by PKR leads to increased translation of ATF4, which then increases expression of CHOP. ATF4 and CHOP trigger activation of autophagy by inducing transcription of essential autophagy genes. In addition, CHOP promotes apoptosis during periods of prolonged cellular stress. PKR can also induce apoptosis independently of EIF2α phosphorylation via activation of the FADD/caspase-8/caspase-3 pathway. Created with BioRender.com.
Role of PKR in different bacterial infections.
| Bacterium | Experimental model | Method of PKR modulation | Live bacterium | Effect of PKR modulationa | Bacterial burdena | Citation |
|---|---|---|---|---|---|---|
|
| Human cardiac myocytes | Pharmacological inhibition | No (RNA) | Decreased apoptosis | N.D | ( |
|
| Mouse BMDMs | Genetic deletion | Yes | Decreased apoptosis | N.D | ( |
| Mouse peritoneal macrophages | Genetic deletion | No (toxin) | Decreased pyroptosis | N.D | ( | |
| Decreased inflammasome activation | ||||||
| J774 macrophages | siRNA knockdown | No (toxin) | Decreased pyroptosis | N.D | ( | |
| Decreased inflammasome activation | ||||||
|
| Mouse BMDCs and BMDMs | Pharmacological inhibition | Yes | Reduced expression of CHOP | N.D | ( |
|
| Mouse BMDMs | Genetic deletion | Yes | Decreased apoptosis | N.D | ( |
| Mouse peritoneal macrophages | Genetic deletion | Yes | Decreased pyroptosis | N.D | ( | |
| Decreased inflammasome activation | ||||||
|
| C57BL/6J mice | Genetic deletion | Yes | Decreased inflammasome activation | Decreased (spleen, peritoneal cavity) | ( |
| Mouse peritoneal macrophages | Yes | Decreased pyroptosis | N.D | |||
| Decreased inflammasome activation | ||||||
| Mouse BMDCs | No (RNA) | Decreased inflammasome activation | ||||
| C57BL/6J mice | Genetic deletion | Yes | N.D | Unaffected (lungs, liver, blood, spleen) | ( | |
| Mouse peritoneal macrophages | Decreased IFNα and IFNβ | N.D | ||||
| C57BL/6J mice | Genetic deletion | Yes | Decreased IL-1β mRNA in the liver | Unaffected (blood) | ( | |
| Human cardiac myocytes | Pharmacological inhibition | No (RNA) | Decreased apoptosis | N.D | ( | |
|
| Mouse BMDMs | Genetic deletion | Yes | Decreased apoptosis | N.D | ( |
|
| MEFs | Genetic deletion | Yes | Increased bacterial invasion | N.D | ( |
| Human mDCs | Pharmacological inhibition | Yes | Decreased IFNβ | N.D | ( | |
| Mouse BMDMs | Genetic deletion | Decreased IFNβ mRNA | ||||
|
| U937 macrophages | shRNA knockdown | Yes | Decreased IL-6 | Unaffected | ( |
|
| Human primary monocytes | Pharmacological inhibition | Yes | Decreased IL-6, TNFα, IL-10 | N.D | ( |
|
| C57BL/6J mice | Genetic deletion | Yes | No effect | Unaffected | ( |
| THP-1 monocytes | Genetic deletion | Yes | N.D | Increased | ( | |
| Pharmacological activation | Decreased | |||||
| THP-1 macrophages | Genetic deletion | Yes | Decreased selective autophagy | Increased | ( | |
| Genetic overexpression | Increased selective autophagy | Decreased |
aBased on “Method of PKR modulation” column. N.D, not determined.
Figure 2Potential mechanisms of PKR activation during bacterial infections. TLR2 and TLR4 on the host cell surface recognize bacterial lipids, proteins, and lipoproteins, or lipopolysaccharide (LPS), respectively. Endosomal TLR9 recognizes CpG motifs found in bacterial RNA, DNA, and peptidoglycan, whereas endosomal TLR3 is activated by bacterial dsRNA. TLR2, TLR4, TLR9, and TLR3 trigger PKR phosphorylation by unknown mechanisms. Furthermore, TLR3 and TLR4 activate TBK1 by their adaptor proteins (TRIF for TLR3 and TRAM and TRIF for TLR4) which goes on to induce phosphorylation and dimerization of IRF3. IRF3 translocates to the nucleus and induces transcription of IFNβ. IFNβ signals through IFNAR to trigger assembly and nuclear translocation of ISGF3, which regulates the PKR promoter to induce transcription of PKR. TLR2 signaling also triggers association of ISGF3 with the PKR promoter. As such, TLR3, TLR4, and TLR2 may induce PKR transcription by downstream activation of ISGF3. Cytosolic bacterial DNA is recognized by cGAS, which associates with G3BP1. G3BP1 co-localizes with PKR and may directly phosphorylate the kinase. Recognition of bacterial DNA triggers cGAS to synthesize the secondary messenger cyclic GMP-AMP. GMP-AMP triggers activation and dimerization of STING, which in turn activates the TBK1-IRF3-IFNβ-ISGF3 axis to induce PKR transcription. In addition, certain bacteria induce ER stress, which triggers phosphorylation of PACT, a cellular activator of PKR. Phosphorylation of PACT enhances its association with PKR and leads to PKR activation. Finally, cytosolic bacterial RNA can directly bind PKR and trigger its activation. Created with BioRender.com.
Pharmacological modulators of PKR.
| Compound | Method of PKR modulation | Stage of development | Animal model | Disease context | Citation | |
|---|---|---|---|---|---|---|
|
| Bozepinib | Unknown | Pre-clinical | N/A | N/A | ( |
| Nitazoxanide | Depletes intracellular Ca2+ stores, resulting in ER stress and PKR phosphorylation | FDA approved | Rats, mice, hamsters | Microbial infections cancer, inflammation, neuropathic pain, Parkinson’s disease | ( | |
| BEPP | Unknown | Pre-clinical | N/A | N/A | ( | |
| DHBDC | Unknown | Pre-clinical | N/A | N/A | ( | |
|
| C16 | Competitive inhibitor of ATP | Pre-clinical | Rats, mice | Neurodegeneration, hypertension, cancer, diabetes, rheumatoid arthritis, inflammation | ( |
| 2-Aminopurine | Competitive inhibitor of ATP | Pre-clinical | Mice | Inflammation, diabetes | ( |
N.A, not applicable.